Refine by
Lupus Articles & Analysis
29 news found
Also based on the positive results in psoriasis patients, we presented our development plan for ‘3667, confirming the start of a Phase 2 study in dermatomyositis (GALARISSO) around year-end and the intention to start a Phase 2 study in systemic lupus erythematosus (SLE) in 2023. We also presented an update on our SIKi portfolio, a potential novel mode-of-action in ...
For those who have recently suffered from vitiligo, psoriasis, systemic lupus erythematosus, and have undergone chemical peeling, grinding and other skin resurfacing procedures , Those who use retinoic acid drugs in the near future need to seriously inquire about the records, and inform them of possible risks, so as to avoid medical disputes caused by factors other than treatment ...
The other assets are two previously licensed candidates and three new immune-oncology therapeutic candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. The agreement includes a $1m upfront payment with RubrYc's investors also eligible to receive up to $5m in development milestones over the ...
New Therapeutic Candidates: Three promising immuno-oncology candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. Purchase terms include: An upfront payment of $1 million in iBio’s common stock to RubrYc investors. ...
In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis. The Company’s head office is in Victoria, British Columbia, its U.S. commercial office is in Rockville, Maryland. ...
(NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in achieving the ...
Secondary endpoints include renal response, renal flare, renal outcomes, and changes in urine protein to creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR). “Lupus nephritis is a severe complication of lupus that will occur in up to half of patients diagnosed with SLE,” said Y.K. ...
ERA Congress 2022 Presentations: Title: “Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study” Presenting author: Y.K. ...
(NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. ...
“Aurinia is committed to expanding the body of research supporting the clinical benefits of LUPKYNIS, the first FDA-approved oral therapy available to people living with lupus nephritis,” said Neil Solomons, M.D., Chief Medical Officer at Aurinia. ...
In January 2021, the Company introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts ...
In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts ...
The multi-cytokines detectable by Creative Proteomics include but are not limited to the following: (1) Cancer Cytokines Assay (2) Cytokine Storm Assays (3) Autoimmune Disease Cytokines Assay (4) Inflammation Cytokines Assay (5) Rheumatoid Arthritis Cytokines Assay (6) Atopic Dermatitis Cytokines Assay (7) Osteoporosis Cytokines Assay (8) Apoptosis ...
Equillium is also conducting a Proof of Concept study for its use in systemic lupus erythematosus (SLE) / lupus nephritis (LN) and has expanded its EQUALISE phase 1b study to clinical centres in India. ...
ByBiocon
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, ...
Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies. Systemic lupus erythematosus is a typical systemic autoimmune disease characterized by the loss of autoimmune tolerance and the production of high levels of ...
(NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious ...
From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of autoimmune conditions is clear. ...
(NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic ...